Knowing what's growing: Why ductal and intraductal prostate cancer matter

Mitchell G. Lawrence, Laura H. Porter, David Clouston, Declan G. Murphy, Mark Frydenberg, Renea A. Taylor, Gail P. Risbridger

Research output: Contribution to journalReview ArticleResearchpeer-review

22 Citations (Scopus)


Prostate cancer is a common malignancy, but only some tumors are lethal. Accurately identifying these tumors will improve clinical practice and instruct research. Aggressive cancers often have distinctive pathologies, including intraductal carcinoma of the prostate (IDC-P) and ductal adenocarcinoma. Here, we review the importance of these pathologies because they are often overlooked, especially in genomics and preclinical testing. Pathology, genomics, and patient-derived models show that IDC-P and ductal adenocarcinoma accompany multiple markers of poor prognosis. Consequently, "knowing what is growing" will help translate preclinical research to pinpoint and treat high-risk prostate cancer in the clinic.

Original languageEnglish
Article numberaaz0152
Number of pages15
JournalScience Translational Medicine
Issue number533
Publication statusPublished - 4 Mar 2020

Cite this